PT  - JOURNAL ARTICLE
AU  - Waschkies, Konrad F.
AU  - Soch, Joram
AU  - Darna, Margarita
AU  - Richter, Anni
AU  - Altenstein, Slawek
AU  - Beyle, Aline
AU  - Brosseron, Frederic
AU  - Buchholz, Friederike
AU  - Butryn, Michaela
AU  - Dobisch, Laura
AU  - Ewers, Michael
AU  - Fliessbach, Klaus
AU  - Gabelin, Tatjana
AU  - Glanz, Wenzel
AU  - Goerss, Doreen
AU  - Gref, Daria
AU  - Janowitz, Daniel
AU  - Kilimann, Ingo
AU  - Lohse, Andrea
AU  - Munk, Matthias H.
AU  - Rauchmann, Boris-Stephan
AU  - Rostamzadeh, Ayda
AU  - Roy, Nina
AU  - Spruth, Eike Jakob
AU  - Dechent, Peter
AU  - Heneka, Michael T.
AU  - Hetzer, Stefan
AU  - Ramirez, Alfredo
AU  - Scheffler, Klaus
AU  - Buerger, Katharina
AU  - Laske, Christoph
AU  - Perneczky, Robert
AU  - Peters, Oliver
AU  - Priller, Josef
AU  - Schneider, Anja
AU  - Spottke, Annika
AU  - Teipel, Stefan
AU  - Düzel, Emrah
AU  - Jessen, Frank
AU  - Wiltfang, Jens
AU  - Schott, Björn H.
AU  - Kizilirmak, Jasmin M.
TI  - Machine learning-based classification of Alzheimer’s disease and its at-risk states using personality traits, anxiety, and depression
AID  - 10.1101/2022.11.30.22282930
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.11.30.22282930
4099  - http://medrxiv.org/content/early/2023/07/12/2022.11.30.22282930.short
4100  - http://medrxiv.org/content/early/2023/07/12/2022.11.30.22282930.full
AB  - Background Alzheimer’s disease (AD) is often preceded by stages of cognitive impairment, namely subjective cognitive decline (SCD) and mild cognitive impairment (MCI). While cerebrospinal fluid (CSF) biomarkers are established predictors of AD, other non-invasive candidate predictors include personality traits, anxiety, and depression, among others. There predictors offer non-invasive assessment and exhibit changes during AD development and preclinical stages.Methods In a cross-sectional design, we comparatively evaluated the predictive value of personality traits (Big Five), geriatric anxiety and depression scores, resting-state functional magnetic resonance imaging activity of the default mode network, apoliprotein E (ApoE) genotype, and CSF biomarkers (tTau, pTau181, Aβ42/40 ratio) in a multi-class support vector machine classification. Participants included 189 healthy controls (HC), 338 individuals with SCD, 132 with amnestic MCI, and 74 with mild AD from the multicenter DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE).Results Mean predictive accuracy across all participant groups was highest when utilizing a combination of personality, depression, and anxiety scores. HC were best predicted by a feature set comprised of depression and anxiety scores and participants with AD were best predicted by a feature set containing CSF biomarkers. Classification of participants with SCD or aMCI was near chance level for all assessed feature sets.Conclusion Our results demonstrate predictive value of personality trait and state scores for AD. Importantly, CSF biomarkers, personality, depression, anxiety, and ApoE genotype show complementary value for classification of AD and its at-risk stages.Key Points– Multi-class support vector machine classification was used to compare the predictive value of well-established and non-invasive, easy-to-assess candidate variables for classifying participants with healthy cognition, subjective cognitive decline, amnestic mild cognitive impairment, and mild Alzheimer’s disease.– Personality traits, geriatric anxiety and depression scores, resting-state functional magnetic resonance imaging activity of the default mode network, ApoE genotype, and CSF biomarkers were comparatively evaluated.– A combination of personality, anxiety, and depression scores provided the highest predictive accuracy, comparable to CSF biomarkers, indicating complementary value.– Established and candidate predictors had limited success in classifying SCD and aMCI, underscoring the heterogeneity of these cognitive states and emphasizing the need for standardizing terminology and diagnostic criteria.Competing Interest StatementF. Jessen received fees for consultations and presentations between 2019 and 2022 from AC Immune, Biogen, Danone/Nutricia, Eisai, GE Healthcare, Grifols, Janssen, Lilly, MSD, Novo Nordisk, and Roche. E. Düzel is cofounder of neotiv GmbH. The remaining authors report no disclosures relevant to the manuscript.Clinical Protocols https://drks.de/search/de/trial/DRKS00007966 Funding StatementThe study was funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen [DZNE]), reference number BN012.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by Institutional Review Boards of all participating study centers of the DZNE. The process was led and coordinated by the ethical committee of the medical faculty of the University of Bonn (registration number 117/13).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll scripts used to perform the analyses are available under https://github.com/jmkizilirmak/DELCODE162. Data can be made available to cooperation partners of the DZNE after setting up appropriate data sharing contracts. https://github.com/jmkizilirmak/DELCODE162